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Abstract
FBXW7 acts as a tumor suppressor through ubiquitination and degradation of multiple oncoproteins. Loss of FBXW7
expression, which could be partially attributed by the genomic deletion or mutation of FBXW7 locus, is frequently observed
in various human cancers. However, the mechanisms regulating FBXW7 expression still remain poorly understood. Here we
examined the 59 region of FBXW7 gene to investigate the regulation of FBXW7 expression. We identified seven alternative
splicing (AS) 59-UTR forms of FBXW7a that are composed of multiple novel non-coding exons. A significant difference in
translational efficiency among these 59-UTRs variants was observed by in vivo Luciferase reporter assay and Western blot.
Furthermore, we found that the mRNA level of the AS form with high translational efficiency was specifically reduced in
more than 80% of breast cancer cell lines and in more than 50% of human primary cancers from various tissues. In addition,
we also identified mutations of FBXW7 in prostate cancers (5.6%), kidney cancers (16.7%), and bladder cancers (18.8%). Our
results suggest that in addition to mutation, differential expression of FBXW7a AS forms with different translational
properties may serve as a novel mechanism for inactivation of FBXW7 in human cancer.
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Introduction
The FBXW7 gene is a transcriptional target of p53, whose
expression is upregulated in a p53-dependent-manner after
radiation treatment [1]. The FBXW7 gene encodes an F-box
protein, which is essential for the ubiquitination of different
oncoproteins, including c-Myc [2,3], c-Jun [4], cyclin E [5,6],
different members of the Notch family [7,8], Aurora-A [1,9],
mTor [10,11], and KLF5 [12,13]. Overexpression of several of
these targets, such as cyclin E [14], c-Myc [15] and Aurora-A [16]
has been implicated to induce genomic instability. These
observations demonstrated that FBXW7 is a human tumor
suppressor gene, a conclusion that is also supported by the
discovery of FBXW7 gene mutations in cancers from a wide
spectrum of human tissues, such as bile duct, blood, bone, brain,
breast, colon, endometrium, stomach, lung, ovary, pancreas, and
prostate, with overall 6% point mutation frequency [17].
Deletion of the Fbxw7 gene in mice leads to embryonic lethality,
but heterozygous mice develop normally [18,19]. Although they
do not develop spontaneous tumors, radiation exposure gives rise
to different types of tumors, including a range of epithelial cancers
[1]. Mice that carry inactivated alleles of both Fbxw7 and p53 show
acceleration of tumor development. Haploinsufficient loss of
Fbxw7 is observed in most lymphomas in this mouse model, even
those arising from Fbxw7/p53 double heterozygous mice, i.e., loss
of only one copy of the gene can generate a substantial biological
impact [1]. Similar observations of heterozygous mutations were
subsequently found in human tumors [20]. It is therefore likely
that the overall impact of this tumor suppressor gene in human
cancer is greater than the 6% point mutation frequency mentioned
above, since loss of only one gene copy can have a substantial
effect on tumor development. Deletions of chromosome 4q31, on
which FBXW7 is located, are common in many types of human
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cancers [21–25], suggesting that disruption of this pathway may be
a major feature of many, or even a majority, of human cancers.
The 59 untranslated region (59-UTR) plays an important role in
the control of eukaryotic gene expression [26]. Recent studies on
the mammalian transcriptome suggest that most of the genes
express multiple alternative splicing (AS) 59-UTRs, and UTR
heterogeneity for a specific gene likely has a differential effect on
protein expression [27,28]. Notably, many oncogenes and tumors
suppressor genes are also apt to express atypically complex 59-
UTRs [29,30]. In addition, it is becoming clear that inappropriate
expression of 59-UTR AS has been shown to contribute to the
development of cancer [31,32].
In the present study, we investigated 59 region of FBXW7 to
understand its regulatory mechanisms, and identified multiple
novel non-coding exons in FBXW7a isoform, which produced
multiple 59-UTR AS forms. The functional impact of these 59-
UTRs on the efficiency of translation was shown to subsequently
regulate FBXW7a expression. FBXW7a 59-UTRs are differen-
tially expressed between various normal and tumor tissues, which
likely results in the change in the levels of FBXW7a expression
during carcinogenesis. Our findings in this study suggest that
differential expression of FBXW7a AS forms serves a new
mechanism inactivating FBXW7 in human cancer.
Results
Multiple novel alternative splicing forms identified in
FBXW7 gene
Three FBXW7 isoforms (a, b and c) have been reported so far.
They differ in the first exon and share the following 2–11 exons. In
order to examine the regulation of FBXW7 expression, we
characterized the 59 region of FBXW7a, b and c isoform using
the 59 RACE technique with cDNA from the human mammary
epithelial cell (HMEC) 184A1. Sequencing analysis of 115 RACE
clones revealed five novel non-coding exons within FBXW7a 59-
UTR when aligned with the human genomic sequence, whereas
no additional exons were detected from FBXW7b and FBXW7c by
sequencing 27 and 31 RACE clones respectively (Figure 1). The
FBXW7a 59-UTR undergoes alternative splicing (AS) to produce
seven mRNA transcripts with the same primary translation
initiation site (Figure 1, Table S2). These results were further
confirmed by blasting the sequences against the database of
Expressed Sequence Tags (dbEST). The sequences of seven
alternative splicing forms were deposited in Genebank with access
number HQ873864-HQ873870.
Among these exons, 1aa and 1ac appear in most of AS forms,
whereas 1ad is only in one out of seven splicing forms (Figure 1).
Interestingly, 1ab and 1ad seem unlike to coexist in the same AS
form. In order to confirm this, we designed specific PCR primers
corresponding to the sequences in 1ab and 1ad, respectively
(Figure S1) and were unable to detect any band from tissues
mRNA used in this study by RT-PCR (data not shown). In
addition, there are no new ORF found in all seven AS forms of
FBXW7a, indicating that these new exons only form different 59-
UTR regions of different AS forms.
Differences in the translation efficiency of different
FBXW7a AS forms
To investigate the functional effect of these 59-UTRs on the
translational efficiency of subsequent FBXW7aORF, we first used
a luciferase reporter assay to compare seven 59-UTR sequences.
To this end, we cloned each 59-UTR upstream of the firefly
luciferase (LUC) gene in the pGL3 promoter reporter vector
(Promega), and transfected them into HeLa cells. Empty pGL3-
promoter was used as a control (LUC-ctrl). Renilla-normalized
luciferase activity for each construct was compared with the LUC-
ctrl. The results of these assays consistently showed the significant
differences in LUC activities among these seven 59-UTR variants
(Figure 2A). Spli2-UTR always exhibited the highest LUC activity
while the level of LUC activity in Spli1-UTR, Spli4-UTR, and
Spli5-UTR was intermediate, but significantly higher than LUC-
ctrl; the LUC activity of Spli3-UTR, Spli6-UTR, and Spli7-UTR
was not statistically significant in comparison with LUC-ctrl
(Figure 2A). In order to corroborate that these differences in LUC
activity were not due to the variations in LUC transcription, we
performed quantitative real time RT-PCR (qRT-PCR). As
showed in Figure 2B, there were no significant differences in the
levels of LUC transcription among different 59-UTR variants
when compared to LUC-ctrl. This result clearly indicates that the
59-UTRs of FBXW7a regulates the translational efficiency of
downstream ORFs.
To further verify the impact of 59-UTRs on the regulation of
translation, we cloned seven 59-UTRs into upstream of the
FBXW7a ORF in pcDNA3.1 tagged with HA epitope and
subsequently transfected them into Hela cells. Western blotting
analysis showed expression level from the Spli2 construct was
consistently higher than that observed with the other UTRs and
control constructs when normalized to the level of transfection
efficiency control GFP protein (Figure 2C), which is consistent
with the results from the luciferase reporter assay. We confirmed
that the expression difference is not due to transcriptional effects
since mRNA levels are not significantly different (Figure 2D).
Taken together, we concluded that the 59-UTR variants of
FBXW7a have translational modulatory function.
Expression profiles of FBXW7a AS forms in human normal
tissues
Given that 59-UTR can regulate the translation of downstream
ORFs, we next sought to investigate the expression pattern of
FBXW7a AS forms in human tissues. For this purpose, semi-
quantity RT-PCR was performed on 21 human normal tissues
with different sets of primers corresponding to newly identified
exons (Figure 1, Table S1). RT-PCR was initially performed with
a pair of primers (F2/Rs1) that could detect all AS forms. As
expected, multiple AS forms were expressed in all human tissues
(Figure 3A, upper panel). The AS form Spli5, Spli4 and Spli2,
corresponding to band sizes 386 bp, 435 bp, 478 bp respectively,
showed high level of mRNA expression (Figure 3A, upper panel),
consistent with our findings in 59 RACE studies, where the
number of clones corresponding to these AS forms were found
much higher frequency (Figure 1). Expression level of different
FBXW7a AS forms varied among tissues. For example, the Spli4
is the dominant form in testes (lane 12 in Figure 3A, upper panel)
whereas the Spli2 is the most expressed one in other tissues
(Figure 3A, upper panel), suggesting a tissue-associated distribution
pattern.
As the seven AS forms contain crossover of several exons in 59-
UTR, it is difficult to distinguish these variants. Thus we designed
the primers F2/R2 located in exon 1aa and 1ac to compare the
expression level of the Spli1&2 (a sum of Spli1 and Spli2
expression) with the forms Spli3-5 (a sum of Spli3, Spli4 and Spli5
expression). We found that Spli1&2 predominantly expressed in
most tissues (Figure 3A, lower panel, and Figure 3B). But some
tissues, such as spleen, thymus and small intestine showed equal
expression levels of Spli1&2 and Spli3-5 (lanes 11, 13 and 16 in
Figure 3A, lower panel, and Figure 3B), while Spli3-5 is only high
expressed in testes (lane 12 in Figure 3A, lower panel, and
Figure 3B).
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Alternated expression of FBXW7a specific AS forms in
human cancers
Since the differential expression of 59-UTR AS forms has been
linked with tumor progression, we investigated the expression
profile of the identified FBXW7a AS forms in human cancer by
semi-quantitative RT-PCR using the same set of primers described
above. The result in a panel of 20 breast cancer cell lines showed
that most breast cancer cell lines have decreased expression levels
of FBXW7a specific AS forms compared with normal human
mammary epithelial cells (HMEC) (184A1 and 184B5) (Figure 4A).
Almost all breast cancer cell lines showed remarkable reduction in
the expression of Spli1&2 whereas there are no changes in the
expression of Spli3-5 compared to the levels in HMECs (Figure 4A,
lower panel, Figure 4B). These observations were further
confirmed in a set of 92 human primary breast cancers. In
comparison to the pooled normal breast tissues, Spli1&2
expression levels showed a significant reduction in more than
50% of tumors. Surprisingly, we found that the Spli3-5 expression
levels showed significant increase in more than 30% of tumors
(Figure 4C and D).
Next we determined whether differential expression of FBXW7a
specific AS also occurred in other types of human cancer. Indeed,
the FBXW7a expression is switched from Spli1&2 to Spli3-5 in
human kidney, prostate and bladder cancers (Figure 4E and F,
Figure S2A and S2B). This differential expression pattern of
FBXW7a AS forms in various human cancers substantially
supports our hypothesis that FBXW7a AS forms involve in the
regulation of FBXW7a during tumorigenesis. Together, our
results suggest that total FBXW7 protein levels may be reduced
in tumor cells through differential expression of FBXW7a AS
forms, and the decrease in FBXW7 abundance substantially affects
its function on ubiquitination and degradation of its targets
(oncoproteins), consequently resulting in tumor development and
progression.
Mutational analysis of FBXW7 in human urological
cancers
Although mutations are rarely detected in breast cancers,
genetic alterations are still found in prostate cancers [35], and
there is no report about the genetic alterations in bladder and
kidney tumors. Additionally, cancer disparities have been found
among different ethnic groups. There is also no report concerning
the FBXW7 mutation spectrum in cancer among Chinese patients.
This intrigues us to examine whether there are mutations and
what is the frequency of the mutations in Chinese cancer patients.
Thus, we performed the mutation analysis of FBXW7 gene in 18
prostate, 24 kidney, and 16 bladder tumor tissues from Chinese
patients. Both mutations and deletions were found in these tumors
as shown by either gel electrophoresis or sequencing map in
Figure 5. Sequencing of shortened RT-PCR fragments confirmed
two bladder samples and one kidney sample have deletions. Of the
bladder tumor deletions, one tumor has a deletion of part of the
exon 8 plus the whole exon 9, while in the other bladder tumor the
whole exon 2 and 3 sequences are missing. The kidney cancer has
a deletion of part of the exons 8 and 10 together with the whole
exon 9 (Figure 5B–D, Table 1). The overall mutation rate of
FBXW7 in prostate cancers is 5.6%, 16.7% in kidney cancers, and
18.8% in bladder cancers from Chinese patients as summarized in
Table 1.
Discussion
This study provides new insights into the mechanisms that
regulate FBXW7a expression through a novel splicing pattern. We
have identified seven novel AS forms of FBXW7a by 59 RACE
technique. Although they produce essentially the same protein, the
FBXW7a AS forms appear to control protein expression via the
regulation of translational efficiency of these AS forms since we
have demonstrated that FBXW7a 59-UTR variants have a
translational modulatory function. Multiple AS forms were only
found in FBXW7a, not in FBXW7b or FBXW7c. Nevertheless, we
Figure 1. Characterization of N terminus of FBXW7 isoforms using 59-RACE and bioinformatics analysis. Structural illustration of
multiple splicing forms of FBXW7a. Seven different splicing forms of FBXW7a were identified by 59-RACE using gene specific primer (GSP) and nest
primer (Rs1). The number of colonies for each splicing form found during screening was shown. The N-terminal sequence of isoform b and c was also
investigated by 59-RACE using the corresponding primers GSPb, GSPc, Nestb and Nestc. The arrows represent the primers used in this study and their
position in the corresponding sequence.
doi:10.1371/journal.pone.0049453.g001
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found that FBXW7a dominantly expressed in almost all of human
tissues examined whereas FBXW7b mRNA is enriched in brain
and thymus and is absent or in trace amount in other tissues, and
FBXW7c mRNA is found to be restricted in heart and skeletal
muscle (Figure S3), which highlights the potential importance of
FBXW7a to the function of FBXW7. Thus the multiple AS forms
presented in FBXW7a may allow the precise regulation of its
expression during biological processes.
We for the first time discovered that the protein levels of
FBXW7a are regulated through translational control by demon-
strating the differential translational efficiency of different
FBXW7a AS forms. The in vivo experiments using LUC reporter
assays consistently showed that the Spli2 form has the highest
translational efficiency in comparison to others. Several factors are
known to determine translational efficiency [33]. The differences
in translational efficiency among FBXW7a 59-UTR variants is
unlikely due to their length, the sequence around translation start
site, and number of start codons within them as the same number
of start codons and the same sequence around translation start site
were found in all FBXW7a 59-UTR variants. The length of Spli2-
UTR is clearly longer than the Spli6-UTR and Spli7-UTR,
shorter than Spli3-UTR, but Spli2 exhibited higher translation
efficiency. In addition, we examined differences in secondary
structures and free energy of each FBXW7a 59-UTR variants
using the online RNA-folding software (http://rna.tbi.univie.ac.
at/cgi-bin/RNAfold.cgi.). There are no significant differences in
the free energy value after normalizing to the length among these
59-UTRs (data not shown). Future studies will be granted to
investigate the potential mechanisms by which 59-UTRs regulate
the translational efficiency.
FBXW7 has emerged as a major human tumor suppressor gene.
Several mechanisms have been reported for inactivation of
FBXW7 in human cancer including mutation, deletion and
hypermethylation [17,21–25,34]. A lot of efforts have focused on
the finding of FBXW7 mutation in various types of human cancer
and have shown that the overall point mutation frequency is only
6% in human cancers [17], but there was substantial variation
across tumor types. Approximately 30% mutation frequency was
found in cholangiocarcinoma and T-cell acute lymphoblastic
leukamias whereas mutation frequencies in prostate, endometrial
cancers as well as gastrointestinal cancer arrange from 4% to 15%
[35]. Consist with these findings, we reported here for the first time
the mutations of FBXW7 detected in human kidney and bladder
tumors with the frequency 16.7% (4/24) and 18.8% (3/16)
(Table 1), respectively. The frequency in prostate tumor from
Chinese population is 5.6%, similar to a previous study carried out
in Caucasians [36].
Figure 2. 59-UTRs of FBXW7a determine the translational efficiency. (A) Effect of FBXW7a 59-UTR variants on LUC activity. LUC reporter
constructs, which contained each FBXW7a 59-UTR upstream of the LUC reporter gene in the pGL3 vector, were transfected into Hela cells. The LUC
activity was measured as the Firefly/Renilla ratio. Results represent the data from three independent experiments. Each experiment was performed in
triplicate. Mean data and standard deviations are shown. *p,0.05 in comparison to LUC-ctr. (B) LUC transcriptional levels were examined by qRT-PCR.
The LUC mRNA contents were normalized to the Renilla mRNA contents for all samples and the relative LUC mRNA for pGL3p (empty vector,
Promega) was arbitrarily considered to be 1 (control). (C) Effect of 59-UTRs on the FBXW7a protein levels. Immunoblot was developed with anti-HA
antibody from extracts with indicated construct. The intensity of pcDNA3.1(+) containing FBXW7a gene (control) was considered as 1. GFP construct
was used as transfection efficiency control, and b–actin as loading control. All transfections were performed in triplicate, and the bars indicate the
standard deviation. *p,0.05 in comparison to control. (D) cDNA frangments for FBXW7 (upper panel), GFP (middle panel) and GAPDH (lower panel)
were specifically amplified by RT-PCR from Hela cells transfected with indicated constructs.
doi:10.1371/journal.pone.0049453.g002
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Most important finding in this study is that the FBXW7 gene is
deregulated through differential expression of AS forms in human
cancers. The connection between tumor development and
deregulation of AS have become a novel and important aspect
of cancer biology. Our results show that the transcriptional pattern
of FBXW7 AS forms in human cancers is different from normal
tissue compartment. As shown in Figure 4, the FBXW7a
expression patterns in the majority of human cancers are switched
from Spli1&2 to Spli3-5 in comparison to their normal tissue. The
consequence of this switch causes the reduction of FBXW7 protein
level, and in turn leads to partial loss of its function. This result
suggests that deregulated AS of FBXW7a gene may be an
additional mechanism to inactivate FBXW7 in human cancers.
Since differential expression of FBXW7a AS forms has been found
in more than 50% of cancers, we proposed that this new
mechanism plays a major role in human cancer development.
In conclusion, by analyzing FBXW7 59 end region, we identified
the novel FBXW7a 59-UTR variants that regulate FBXW7a gene
expression through the mechanism involving translational effi-
ciency. These AS forms are expressed in a tissue-associated
manner with varied levels among different tissues. Our study
provides a new insight into the alteration of FBXW7a expression
during human cancer development.
Materials and Methods
Ethics statement
The human primary breast tumors were collected at the time of
surgical resection at Hospital Universitario of Salamanca,
Salamanca, Spain. Collection and the use of patient samples were
approved by the institutional ethics review board of the Hospital
Universitario of Salamanca. The human primary prostate, bladder
and kidney tumors were collected at the time of surgical resection
at Changhai Hospital, China. The collection and the use of patient
samples were approved under the institutional ethics review board
of Changhai Hospital, Second Military Medical University.
Written informed consent was obtained from all patients for
research using these tumor samples.
Patient samples
In both hospitals, the fresh tumor tissue samples were obtained
at the time of surgical resection of patient tumors. The samples
were immediately snap-frozen down in liquid nitrogen and then
storage at 280uC freezer before use. H&E (hematoxylin and eosin
stained) slides of frozen human tumor tissues were examined by
the pathologists of this study to ensure that the tumor tissues
selected had high-density cancer foci (.80%).
Cell lines
Breast cancer cell lines were cultured in DMEM or in
RMPI1640 supplemented with 10% fetal bovine serum and
100 mM Streptomycin and Penicillin; details were described in
our previous study [37]. Hela cells were cultured in MEM with
10% fetal bovine serum and 100 mM Streptomycin and Penicillin.
Cells were incubated at 37uC in a humidified incubator with 5%
CO2.
Total RNA extraction from cells and tissue
Total RNAs were prepared from 80% confluent culture of
breast cancer cell lines, Hela cells 36 hr post transfection and
Figure 3. mRNA expression profile of FBXW7a AS forms in human normal tissues. (A) FBXW7a AS forms expression levels were detected by
semi-quantitative RT-PCR using different pairs of primers. (B) The levels of Spli1&2 and Spli3-5 expression were quantified from the experiment shown
in (A) lower panel. Normal tissues include: 1-esophagus, 2-adipose, 3-heart, 4-bladder, 5-kidney, 6-brain, 7-liver, 8-lung, 9-cervix, 10-colon, 11-spleen,
12-testes, 13-thymus, 14-thyraoid, 15-trachea, 16-small intestine, 17-skeletal muscle, 18-prostate, 19-placental, 20-ovary, 21-breast. ‘‘M’’ represents
DNAs ladder Marker.
doi:10.1371/journal.pone.0049453.g003
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frozen human breast, kidney, prostate and bladder tumor tissues
using Trizol (Invitrogen) according to the manufacturer’s instruc-
tions. Extracted RNA samples were treated with the DNA-free kit
(Ambion) prior to further analysis, in order to remove any residual
amount of genomic DNA. RNA concentration and quality were
determined with a Nanovue spectrophotometer (GE healthcare).
Human total RNA from different normal tissues was purchased
from Ambion.
59 rapid amplification of cDNA ends (RACE)
The characterization of FBXW7 gene N terminus was carried
out using 59 RACE kit (Invitrogen) according to the manufactur-
er’s instructions. Briefly, total RNA was isolated from the human
mammary epithelial cell (HMEC) 184A1 cells with Trizol
(Invitrogen), and cDNA was generated using specific primer
(GSP) listed in Table S1. The cDNA was tailed with dCTP using
terminal deoxy-transferase, and a poly-G primer (Invitrogen) was
combined with each FBXW7 cDNA for PCR. A second PCR was
carried out with a dilution of the first PCR, using each nest primer
Nesta (Rs1), Nestb or Nestc (Table S1), and an adaptamer primer
provided by Invitrogen. The PCR products were analyzed by gel
electrophoresis and were cloned into pCR4 vector. Each clone was
sequenced.
Reverse transcription and PCR amplification of cDNA
First strand cDNA was synthesized using SuperScript III cDNA
synthesis kit (Invitrogen). 1 mg of RNA was subjected to reverse
transcription following the reaction conditions specified by the
manufacture. Reactions were primed with 50 ng of random
hexamers. The cDNAs from breast cancer cell lines, human
normal tissues panel, and primary breast, kidney, prostate and
bladder tumors were analyzed for AS transcripts of FBXW7a using
PCR with primer pairs F2/RS1, F2/R2 and F1/Rs1 (Table S1).
The housekeeper gene GAPDH was amplified as control by the
primer pair GapF/GapR (Table S1). The protocol for the PCR
reaction was 26–35 cycles of denaturation at 95uC for 30 s,
annealing at 56uC for 30 s, and extension at 72uC for 30 s.
To detect FBXW7 mutations in primary prostate, bladder, and
kidney tumors, the coding sequence of FBXW7 was amplified by
RT-PCR using three primer pairs P1F/R, P2F/R and P3F/R
(Table S1), and the amplified products were sequenced and
compared in the Genebank Database. For different sized PCR
products, bands were gel excised and purified, and then verified by
DNA sequencing.
Plasmid constructs
Seven different FBXW7a 59-UTRs (Spli1 to 7) were amplified
from those positive pCR4 clones in RACE using the following
primer pair GL3F/GL3R (Table S1). The PCR products were gel-
purified, digested and then ligated into pGL3-promoter vector
(Promega) via HindIII/NcoI restriction sites immediately adjacent
to the downstream luciferase gene. The generated constructs were
designated as Spli1-UTR, Spli2-UTR, Spli3-UTR, Spli4-UTR,
Spli5-UTR, Spli6-UTR, and Spli7-UTR. Similarly, seven 59-
UTRs amplified by primer pair GL3F/GL3R2 were introduced
into upstream of FBXW7a gene fused with HA epitope in
pcDNA3.1 (+) vector (saved in this laboratory) via HindIII/EcoRI.
All constructs were verified by DNA sequencing.
Figure 4. Differential change in mRNA expression level of FBXW7a AS forms in human cancer. (A) mRNA expression profile of FBXW7a
AS forms in human breast cancer and HMEC cell lines was determined by semi-quantitative RT-PCR using different sets of primers. ‘‘b1 to b20’’
represents 20 different breast cancer cell lines, ‘‘A1’’ stands for 184A1, ‘‘B5’’ for 184B5. (B) The levels of Spli1&2 and Spli3-5 expression were quantified
from the experiment shown in (A) lower panel. (C) The representative mRNA expression profile of FBXW7a AS forms from 92 human primary breast
cancers by semi-quantitative RT-PCR using different sets of primers. (D) Quantification of Spli1&2 and Spli3-5 expression levels in 92 human primary
breast cancers. (E) The mRNA expression profile of FBXW7a AS forms in 24 human primary kidney cancers by semi-quantitative RT-PCR using different
sets of primers. (F) Quantification of Spli1&2 and Spli3-5 expression levels in 24 human primary kidney cancers. ‘‘N’’ for pooled RNAs from normal
tissues, ‘‘M’’ for DNAs ladder Marker.
doi:10.1371/journal.pone.0049453.g004
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Transient transfection
Transient transfections were performed on about 70% confluent
HeLa cells using the Lipofectamine 2000 reagent (Invitrogen).
Twenty-four hours before transfection, cells were trypsinized and
transferred to either 96-well plates (for luciferase assay) or 60 mm
dishes (for RNA isolation). Transfection was performed with the
reagent following the manufacture’s protocol. Briefly, 0.2 mg of
experimental DNA from large-scale plasmid preparations was
delivered to the each well in the 96-well plates in the presence of
phRL-TK Renilla luciferase control plasmid (Promega, 0.01 mg) or
4 ug of experimental DNA and 0.2 mg of Renilla luciferase control
plasmid to the cells seeded in 60 mm dish, and cells were
Figure 5. Mutational analysis of FBXW7 in primary prostate, bladder, and kidney cancers from the Chinese patients. (A) RT-PCR
analysis of FBXW7, RT–PCR products containing deletions are indicated by asterisk. (B–D) sequencing confirmed the deletion in two bladder cancers
(B and C), and a kidney cancer (D). (E) Representative sequence traces showing the mutations of FBXW7.
doi:10.1371/journal.pone.0049453.g005
Table 1. Mutations in FBXW7 gene in urological cancer from Chinese patients.
Tumor type Frequency Nucleotide or deletion (cDNA)* Amino acid (protein)
Prostate 1/18 C383T S128T
Kidney 4/24 T1453C V485A
G1699A# D567N
A1750C# T584P
A1792G N598D
del1270–1758 (part of exon8, exon9,
and part of exon10)
Bladder 3/16 A492C K164N
del502–727 (exon 2&3)
del1390–1644 (part of exon 8,
and exon 9)
*Nucleotide and protein position from the start codon based on FBXW7a isoform.
#two mutations from one sample.
doi:10.1371/journal.pone.0049453.t001
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incubated at 37uC. After 4 hours, medium was replaced by
DMEM with 10% FBS and antibiotics/antimycotics, and cells
were incubated until used for RNA extraction or luciferase assay.
After 6 hours, medium was replaced by DMEM with 10% FBS,
and cells were incubated until used for RNA extraction or
luciferase assay.
Wesstern blot
Hela cells were co-transfected by ten micrograms each of
pcDNA3.1containing alternative splicing form and pEGFP-C1
(Promega) for 48 hr and harvested by RIPA buffer (sigma). Fifty
micrograms of protein was resolved on an 4–12% gradient SDS-
polyacrylamide gel (Invitrogen) and electrotransfered to a PVDF
membrane. Antibodies used in this study were anti-HA antibody
(Sigma, clone HA-7), anti-GFP (cell signaling) and anti-beta-actin
(Sigma, clone AC-15), and goat anti-mouse HRP-conjugated
secondary antibody. Blots were developed with SuperSignal
substrate (Thermo Scientific) and quantified using ImageJ
software.
Luciferase activity assay
Transfected cells were harvested after 36 hours, and both
Firefly and Renilla luciferase activities were measured with the
Dual-luciferase reporter assay system kit (Promega) according to
the manufacturer’s protocol using Modulus II microplate multi-
mode reader (Turner Biosystem). Briefly, the cells were rinsed
twice with 16 PBS and lysed in 40 ml of 16 passive lysis buffer
(PLB) following gently rocking for 15 min at room temperature.
For Firefly luciferase activity, 100 ml of LARII (luciferase assay
reagent II) was added to each well and mixed by slightly tapping
the plate. Place the plate in the luminometer and initiate reading.
And then add 100 ml of Stop and Glo reagent to stop Firefly
luciferase activity and simultaneously activate the Renilla lucifer-
ase activity, then place the plate in the luminometer for reading.
Results are expressed by the ratio of Firefly to Renilla luciferase
activities.
Measurement of luciferase mRNA level using real-time
RT-PCR
The amount of luciferase mRNA was determined by real-time
RT-PCR using the Bio-rad CFX96 Real-Time PCR system and
the Power SYBR Green Master mix (Applied Biosystems),
according to the manufacturer’s instructions. Renila luciferase
was used as an internal control. The PCR conditions were 95uC
for 10 min, and 40 cycles of 95uC for 15 s and 60uC for 1 min and
95uC for 1 min. The primers used for luciferase were LucF and
LucR, and for Renila luciferase are ReniF and ReniR (Table S1).
Statistical analysis
At least three independent experiments were carried out for
transfection, mRNA quantification and luciferase assays. Differ-
ences among treatment groups were estimated by one-way
ANOVA followed by the Tukey’s multiple comparisons test using
the Originlab7.5 software. The results are expressed as means 6
standard deviation. Statistically significant differences were con-
sidered when p,0.05.
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Figure S1 Genomic structure of FBXW7a. 1aa, 1ac, 1ab and
1ae are additional exons identified in this study.
(DOC)
Figure S2 Differential change in mRNA expression level of
FBXW7a AS forms in human prostate (A) and bladder (B)
cancers. The mRNA expression profile of FBXW7a AS forms was
determined by semi-quantitative RT-PCR. ‘‘M’’ for DNAs ladder
Marker.
(DOC)
Figure S3 The mRNA levels of Fbxw7a, Fbxw7b and Fbxw7c
in the different tissues were determined by RT-PCR analysis using
corresponding primer pairs (Forward primers: Fa, Fb, Fc, and
common reverse primer cdc4R) listed in Table S1. Normal tissues
include: 1-esophagus, 2-adipose, 3-heart, 4-bladder, 5-kidney, 6-
brain, 7-liver, 8-lung, 9-cervix, 10-colon, 11-spleen, 12-testes, 13-
thymus, 14-thyraoid, 15-trachea, 16-small intestine, 17-skeletal
muscle, 18-prostate, 19-placental, 20-ovary, 21-breast. ‘‘M’’
represents DNAs ladder Marker.
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